| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Ischemia | 30 | 2018 | 345 | 5.300 |
Why?
|
| Myocardial Infarction | 35 | 2023 | 1051 | 4.070 |
Why?
|
| Stem Cell Transplantation | 20 | 2022 | 239 | 3.810 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 13 | 2021 | 86 | 3.210 |
Why?
|
| Bone Marrow Transplantation | 24 | 2017 | 575 | 2.990 |
Why?
|
| Ventricular Dysfunction, Left | 15 | 2021 | 370 | 2.490 |
Why?
|
| Heart Failure | 25 | 2023 | 2300 | 2.470 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2017 | 180 | 2.110 |
Why?
|
| Cell- and Tissue-Based Therapy | 9 | 2023 | 164 | 1.840 |
Why?
|
| Wearable Electronic Devices | 2 | 2023 | 103 | 1.470 |
Why?
|
| Regeneration | 5 | 2021 | 214 | 1.440 |
Why?
|
| Ventricular Function, Left | 16 | 2023 | 510 | 1.430 |
Why?
|
| Heart | 11 | 2022 | 730 | 1.390 |
Why?
|
| Aldehyde Dehydrogenase | 4 | 2017 | 40 | 1.330 |
Why?
|
| Myocardium | 12 | 2017 | 1023 | 1.320 |
Why?
|
| Bone Marrow Cells | 12 | 2017 | 264 | 1.220 |
Why?
|
| Transplantation, Autologous | 20 | 2018 | 300 | 1.160 |
Why?
|
| Coronary Angiography | 13 | 2023 | 450 | 1.130 |
Why?
|
| Coronary Restenosis | 5 | 2015 | 23 | 1.110 |
Why?
|
| Endocardium | 10 | 2016 | 51 | 1.090 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2023 | 30 | 1.070 |
Why?
|
| Coronary Circulation | 7 | 2012 | 216 | 1.050 |
Why?
|
| Electrocardiography | 12 | 2022 | 978 | 1.010 |
Why?
|
| Coronary Artery Disease | 10 | 2017 | 814 | 0.990 |
Why?
|
| Extremities | 3 | 2017 | 83 | 0.960 |
Why?
|
| Coronary Vessels | 9 | 2017 | 558 | 0.930 |
Why?
|
| Stents | 10 | 2017 | 889 | 0.900 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 1122 | 0.880 |
Why?
|
| Disease Models, Animal | 11 | 2021 | 4409 | 0.870 |
Why?
|
| Stem Cells | 8 | 2022 | 711 | 0.870 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2023 | 69 | 0.870 |
Why?
|
| Peripheral Arterial Disease | 3 | 2017 | 292 | 0.850 |
Why?
|
| Swine | 15 | 2022 | 1209 | 0.830 |
Why?
|
| Radiation Exposure | 1 | 2023 | 42 | 0.820 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2016 | 1204 | 0.820 |
Why?
|
| Double-Blind Method | 16 | 2019 | 1636 | 0.800 |
Why?
|
| Injections | 12 | 2016 | 155 | 0.790 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 253 | 0.760 |
Why?
|
| Cardiovascular Diseases | 7 | 2018 | 1972 | 0.740 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2022 | 210 | 0.740 |
Why?
|
| Stroke Volume | 11 | 2023 | 491 | 0.740 |
Why?
|
| Regenerative Medicine | 2 | 2018 | 31 | 0.720 |
Why?
|
| Intermittent Claudication | 3 | 2017 | 58 | 0.700 |
Why?
|
| Diabetic Foot | 1 | 2023 | 163 | 0.690 |
Why?
|
| Coronary Disease | 8 | 2008 | 679 | 0.680 |
Why?
|
| Humans | 110 | 2023 | 125667 | 0.680 |
Why?
|
| Congresses as Topic | 2 | 2018 | 175 | 0.670 |
Why?
|
| Antigens, CD34 | 5 | 2016 | 109 | 0.660 |
Why?
|
| Heart Diseases | 7 | 2018 | 495 | 0.640 |
Why?
|
| Sirolimus | 5 | 2022 | 227 | 0.630 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 275 | 0.630 |
Why?
|
| Drug-Eluting Stents | 4 | 2012 | 64 | 0.620 |
Why?
|
| Cell Differentiation | 8 | 2022 | 1912 | 0.620 |
Why?
|
| Oxygen | 1 | 2022 | 557 | 0.620 |
Why?
|
| Adipose Tissue | 3 | 2022 | 465 | 0.600 |
Why?
|
| Treatment Outcome | 34 | 2021 | 12420 | 0.590 |
Why?
|
| Cardiac Catheterization | 8 | 2023 | 634 | 0.590 |
Why?
|
| Exercise Tolerance | 4 | 2011 | 85 | 0.590 |
Why?
|
| Angina Pectoris | 5 | 2012 | 58 | 0.580 |
Why?
|
| Middle Aged | 51 | 2018 | 27000 | 0.550 |
Why?
|
| Male | 66 | 2021 | 61776 | 0.550 |
Why?
|
| Academies and Institutes | 1 | 2018 | 84 | 0.550 |
Why?
|
| Endothelial Cells | 3 | 2011 | 527 | 0.540 |
Why?
|
| Nanotubes, Carbon | 4 | 2019 | 19 | 0.540 |
Why?
|
| Tomography, Optical Coherence | 3 | 2017 | 522 | 0.530 |
Why?
|
| Follow-Up Studies | 21 | 2018 | 5195 | 0.520 |
Why?
|
| Animals | 35 | 2022 | 34349 | 0.510 |
Why?
|
| Staining and Labeling | 4 | 2019 | 187 | 0.490 |
Why?
|
| Heart Ventricles | 4 | 2017 | 773 | 0.490 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 3 | 2021 | 61 | 0.490 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2021 | 450 | 0.480 |
Why?
|
| Microcirculation | 3 | 2017 | 96 | 0.480 |
Why?
|
| Genetic Therapy | 4 | 2023 | 688 | 0.480 |
Why?
|
| Stroke | 2 | 2023 | 990 | 0.480 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 875 | 0.470 |
Why?
|
| Aged | 35 | 2018 | 19900 | 0.470 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 154 | 0.470 |
Why?
|
| Immunotherapy | 1 | 2019 | 680 | 0.450 |
Why?
|
| Cell Transplantation | 1 | 2014 | 45 | 0.450 |
Why?
|
| Gadolinium | 4 | 2018 | 108 | 0.440 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 8 | 2012 | 110 | 0.440 |
Why?
|
| Female | 55 | 2021 | 66998 | 0.440 |
Why?
|
| Time Factors | 17 | 2017 | 6351 | 0.430 |
Why?
|
| Neovascularization, Physiologic | 7 | 2013 | 215 | 0.430 |
Why?
|
| Adipocytes | 1 | 2014 | 141 | 0.420 |
Why?
|
| Rejuvenation | 1 | 2012 | 10 | 0.410 |
Why?
|
| Clinical Trials as Topic | 8 | 2015 | 1106 | 0.400 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 48 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2018 | 3597 | 0.400 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2022 | 1122 | 0.400 |
Why?
|
| Coronary Stenosis | 2 | 2017 | 78 | 0.400 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 260 | 0.400 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 738 | 0.400 |
Why?
|
| Pluripotent Stem Cells | 1 | 2013 | 71 | 0.390 |
Why?
|
| Biocompatible Materials | 1 | 2012 | 119 | 0.390 |
Why?
|
| Feasibility Studies | 8 | 2018 | 762 | 0.380 |
Why?
|
| Genetic Vectors | 1 | 2015 | 940 | 0.380 |
Why?
|
| Tissue Engineering | 2 | 2012 | 180 | 0.370 |
Why?
|
| Ischemia | 2 | 2013 | 363 | 0.370 |
Why?
|
| Interleukin-10 | 1 | 2012 | 174 | 0.370 |
Why?
|
| Prospective Studies | 17 | 2017 | 6171 | 0.370 |
Why?
|
| Sus scrofa | 5 | 2018 | 129 | 0.360 |
Why?
|
| Paclitaxel | 2 | 2009 | 130 | 0.360 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 3 | 2001 | 4 | 0.350 |
Why?
|
| Interleukin-6 | 1 | 2012 | 420 | 0.350 |
Why?
|
| Recovery of Function | 5 | 2016 | 446 | 0.350 |
Why?
|
| Colony-Forming Units Assay | 4 | 2014 | 69 | 0.340 |
Why?
|
| Cardiology | 2 | 2018 | 507 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 543 | 0.340 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 306 | 0.320 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 90 | 0.320 |
Why?
|
| Endothelium, Vascular | 2 | 2019 | 527 | 0.320 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 141 | 0.320 |
Why?
|
| Myocytes, Cardiac | 4 | 2021 | 641 | 0.310 |
Why?
|
| Chronic Disease | 6 | 2016 | 1201 | 0.310 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 946 | 0.310 |
Why?
|
| Protein Isoforms | 2 | 2023 | 404 | 0.310 |
Why?
|
| Plasmids | 2 | 2023 | 513 | 0.310 |
Why?
|
| Biological Products | 1 | 2010 | 122 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2109 | 0.300 |
Why?
|
| Myocardial Contraction | 5 | 2011 | 268 | 0.300 |
Why?
|
| Body Surface Potential Mapping | 2 | 2012 | 12 | 0.300 |
Why?
|
| Heart Function Tests | 3 | 2013 | 58 | 0.300 |
Why?
|
| Ultrasonography, Interventional | 2 | 2007 | 192 | 0.280 |
Why?
|
| Wound Healing | 2 | 2009 | 460 | 0.280 |
Why?
|
| Cytokines | 1 | 2012 | 1289 | 0.270 |
Why?
|
| Chest Pain | 2 | 2022 | 129 | 0.270 |
Why?
|
| Echocardiography | 5 | 2021 | 1059 | 0.270 |
Why?
|
| Inflammation | 3 | 2023 | 1447 | 0.270 |
Why?
|
| Contrast Media | 4 | 2019 | 480 | 0.260 |
Why?
|
| Magnetics | 4 | 2013 | 41 | 0.260 |
Why?
|
| Myocardial Revascularization | 2 | 2003 | 103 | 0.250 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 433 | 0.240 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 44 | 0.230 |
Why?
|
| Injections, Intramuscular | 3 | 2016 | 194 | 0.230 |
Why?
|
| Pilot Projects | 4 | 2021 | 1397 | 0.230 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2007 | 101 | 0.230 |
Why?
|
| Leg | 2 | 2016 | 158 | 0.230 |
Why?
|
| Immunosuppressive Agents | 4 | 2013 | 651 | 0.230 |
Why?
|
| Research Design | 7 | 2019 | 695 | 0.230 |
Why?
|
| Quality of Life | 5 | 2021 | 1952 | 0.220 |
Why?
|
| Heart Rate Determination | 1 | 2023 | 2 | 0.220 |
Why?
|
| Cells, Cultured | 3 | 2022 | 3061 | 0.220 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2005 | 166 | 0.220 |
Why?
|
| Radial Artery | 1 | 2023 | 28 | 0.220 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 48 | 0.210 |
Why?
|
| Transplantation, Homologous | 4 | 2015 | 667 | 0.210 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 241 | 0.210 |
Why?
|
| Predictive Value of Tests | 6 | 2022 | 2178 | 0.210 |
Why?
|
| Endpoint Determination | 3 | 2019 | 57 | 0.210 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 2899 | 0.210 |
Why?
|
| Ankle Brachial Index | 2 | 2014 | 42 | 0.210 |
Why?
|
| Ventricular Remodeling | 3 | 2019 | 184 | 0.200 |
Why?
|
| Coronary Thrombosis | 3 | 2017 | 35 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2016 | 801 | 0.200 |
Why?
|
| Swine Diseases | 1 | 2022 | 37 | 0.200 |
Why?
|
| Cardiac Tamponade | 1 | 2022 | 36 | 0.200 |
Why?
|
| Electromyography | 1 | 2003 | 165 | 0.200 |
Why?
|
| Heart Rate | 2 | 2023 | 592 | 0.200 |
Why?
|
| Pericardial Effusion | 1 | 2022 | 65 | 0.190 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2022 | 29 | 0.190 |
Why?
|
| Carotid Stenosis | 3 | 2012 | 143 | 0.180 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 377 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 326 | 0.180 |
Why?
|
| Cell Tracking | 2 | 2018 | 16 | 0.180 |
Why?
|
| Cell Separation | 2 | 2011 | 230 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2022 | 2356 | 0.170 |
Why?
|
| Echocardiography, Doppler | 3 | 2004 | 171 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 2918 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2002 | 249 | 0.170 |
Why?
|
| Dogs | 4 | 2015 | 775 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 432 | 0.170 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 190 | 0.160 |
Why?
|
| Bismuth | 1 | 2019 | 80 | 0.150 |
Why?
|
| Coronary Aneurysm | 1 | 1999 | 33 | 0.150 |
Why?
|
| Acrylic Resins | 1 | 2018 | 25 | 0.150 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 270 | 0.150 |
Why?
|
| Anthracyclines | 1 | 2018 | 36 | 0.150 |
Why?
|
| CD11b Antigen | 2 | 2016 | 36 | 0.150 |
Why?
|
| Software | 1 | 2003 | 686 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 241 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 175 | 0.140 |
Why?
|
| Oxygen Consumption | 2 | 2012 | 305 | 0.140 |
Why?
|
| DNA | 1 | 2023 | 1613 | 0.140 |
Why?
|
| Exercise Test | 4 | 2005 | 254 | 0.140 |
Why?
|
| Hirudins | 1 | 2017 | 37 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 69 | 0.140 |
Why?
|
| Antithrombins | 1 | 2017 | 56 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2016 | 73 | 0.140 |
Why?
|
| Sensitivity and Specificity | 4 | 2007 | 2060 | 0.140 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 16 | 0.130 |
Why?
|
| Organogenesis | 1 | 2017 | 80 | 0.130 |
Why?
|
| Adult | 19 | 2022 | 29734 | 0.130 |
Why?
|
| Fibrosis | 2 | 2011 | 438 | 0.130 |
Why?
|
| Diabetic Angiopathies | 2 | 2008 | 65 | 0.130 |
Why?
|
| Perfusion | 1 | 2017 | 207 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 1273 | 0.120 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2017 | 113 | 0.120 |
Why?
|
| Risk Factors | 6 | 2017 | 10340 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2016 | 4843 | 0.120 |
Why?
|
| Physicians | 1 | 2022 | 589 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 627 | 0.120 |
Why?
|
| Regional Blood Flow | 2 | 2016 | 210 | 0.120 |
Why?
|
| Neointima | 1 | 2015 | 43 | 0.120 |
Why?
|
| Prosthesis Design | 4 | 2013 | 683 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2018 | 215 | 0.120 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 12 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 1995 | 60 | 0.110 |
Why?
|
| Injections, Intralesional | 3 | 2015 | 48 | 0.110 |
Why?
|
| Hemodynamics | 4 | 2013 | 853 | 0.110 |
Why?
|
| Monocytes | 3 | 2008 | 345 | 0.110 |
Why?
|
| Cardiomyoplasty | 1 | 2013 | 6 | 0.110 |
Why?
|
| Antigens, Heterophile | 1 | 2013 | 2 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2017 | 781 | 0.110 |
Why?
|
| Antibodies, Heterophile | 1 | 2013 | 10 | 0.100 |
Why?
|
| Texas | 3 | 2018 | 3588 | 0.100 |
Why?
|
| Hindlimb | 1 | 2013 | 80 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 157 | 0.100 |
Why?
|
| Neoplasms | 2 | 2018 | 2803 | 0.100 |
Why?
|
| Adventitia | 1 | 2012 | 6 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1995 | 215 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 385 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2005 | 355 | 0.100 |
Why?
|
| United States | 5 | 2016 | 10942 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 57 | 0.100 |
Why?
|
| Telomerase | 1 | 2013 | 168 | 0.100 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 172 | 0.100 |
Why?
|
| Random Allocation | 1 | 2013 | 441 | 0.100 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 501 | 0.100 |
Why?
|
| Arabinofuranosyluracil | 1 | 2011 | 4 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2013 | 342 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 1537 | 0.090 |
Why?
|
| Lymphography | 1 | 2011 | 12 | 0.090 |
Why?
|
| Myosin Light Chains | 1 | 2011 | 18 | 0.090 |
Why?
|
| Thy-1 Antigens | 1 | 2011 | 22 | 0.090 |
Why?
|
| Multipotent Stem Cells | 1 | 2011 | 28 | 0.090 |
Why?
|
| Thymidine Kinase | 1 | 2011 | 95 | 0.090 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2011 | 3 | 0.090 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 37 | 0.090 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 27 | 0.090 |
Why?
|
| Dipyridamole | 1 | 1991 | 28 | 0.090 |
Why?
|
| Angioplasty | 1 | 2012 | 89 | 0.090 |
Why?
|
| Endarterectomy, Carotid | 1 | 2012 | 100 | 0.090 |
Why?
|
| Extracorporeal Circulation | 1 | 2011 | 55 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 816 | 0.090 |
Why?
|
| Antibodies, Bispecific | 1 | 2011 | 38 | 0.090 |
Why?
|
| Patient Selection | 2 | 2012 | 701 | 0.090 |
Why?
|
| Nanotubes | 1 | 2010 | 13 | 0.090 |
Why?
|
| Capillaries | 1 | 2011 | 66 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2011 | 240 | 0.090 |
Why?
|
| Bundle-Branch Block | 1 | 1991 | 34 | 0.090 |
Why?
|
| Genes, Reporter | 1 | 2011 | 381 | 0.090 |
Why?
|
| Disease Progression | 1 | 2016 | 2089 | 0.090 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2017 | 63 | 0.080 |
Why?
|
| Equipment Design | 2 | 2013 | 599 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2012 | 3470 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 6607 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 31 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2011 | 302 | 0.080 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 150 | 0.080 |
Why?
|
| Angioplasty, Laser | 2 | 2001 | 2 | 0.080 |
Why?
|
| Heart Arrest | 2 | 2011 | 356 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2011 | 379 | 0.080 |
Why?
|
| Registries | 3 | 2017 | 1436 | 0.080 |
Why?
|
| Ear | 1 | 2009 | 25 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2009 | 26 | 0.080 |
Why?
|
| Swine, Miniature | 1 | 2009 | 49 | 0.080 |
Why?
|
| Myocardial Stunning | 1 | 2009 | 22 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 46 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 800 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 819 | 0.080 |
Why?
|
| Chondrocytes | 1 | 2009 | 50 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 4 | 2015 | 258 | 0.080 |
Why?
|
| Biomarkers | 3 | 2014 | 3095 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 373 | 0.080 |
Why?
|
| Forecasting | 3 | 2012 | 354 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2012 | 1261 | 0.080 |
Why?
|
| Heart Valve Prosthesis | 1 | 1991 | 301 | 0.070 |
Why?
|
| Mitochondria | 1 | 2013 | 680 | 0.070 |
Why?
|
| Electrodes | 1 | 2008 | 99 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 1273 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 411 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2007 | 73 | 0.070 |
Why?
|
| Reference Values | 2 | 2002 | 718 | 0.070 |
Why?
|
| Critical Illness | 1 | 2011 | 601 | 0.070 |
Why?
|
| Cell Line | 1 | 2011 | 2760 | 0.060 |
Why?
|
| Recurrence | 3 | 2004 | 1420 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 44 | 0.060 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2005 | 20 | 0.060 |
Why?
|
| Creatine Kinase | 1 | 2005 | 58 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 556 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2004 | 61 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2005 | 250 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1033 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 232 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2013 | 1027 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2005 | 428 | 0.050 |
Why?
|
| Troponin I | 1 | 2005 | 108 | 0.050 |
Why?
|
| Pain, Intractable | 1 | 2003 | 25 | 0.050 |
Why?
|
| Propanolamines | 1 | 2003 | 32 | 0.050 |
Why?
|
| Carbazoles | 1 | 2003 | 33 | 0.050 |
Why?
|
| Atherectomy | 1 | 2002 | 12 | 0.050 |
Why?
|
| Mice | 3 | 2021 | 17727 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2003 | 107 | 0.050 |
Why?
|
| Cell Movement | 1 | 2006 | 855 | 0.050 |
Why?
|
| Terrorism | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2005 | 941 | 0.050 |
Why?
|
| Pericardium | 1 | 2022 | 83 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 145 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 4273 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 534 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2016 | 16417 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2003 | 244 | 0.040 |
Why?
|
| Minnesota | 1 | 2021 | 133 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 781 | 0.040 |
Why?
|
| ROC Curve | 1 | 2002 | 571 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 1706 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2002 | 1021 | 0.040 |
Why?
|
| Physician's Role | 1 | 2002 | 168 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2007 | 805 | 0.040 |
Why?
|
| Electromagnetic Phenomena | 1 | 2000 | 4 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 590 | 0.040 |
Why?
|
| Dependovirus | 1 | 2021 | 128 | 0.040 |
Why?
|
| Radiography | 2 | 2000 | 824 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 373 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2000 | 271 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 460 | 0.040 |
Why?
|
| Thermogravimetry | 1 | 2018 | 5 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 391 | 0.040 |
Why?
|
| Foreign Bodies | 1 | 2000 | 104 | 0.040 |
Why?
|
| Veins | 1 | 1999 | 108 | 0.040 |
Why?
|
| Coronary Artery Bypass | 2 | 1999 | 518 | 0.040 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2018 | 30 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 57 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2002 | 594 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 134 | 0.040 |
Why?
|
| Autografts | 1 | 2016 | 26 | 0.030 |
Why?
|
| Logistic Models | 2 | 2012 | 1816 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 440 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2016 | 36 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 91 | 0.030 |
Why?
|
| Cardiac Catheters | 1 | 2015 | 8 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 56 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 164 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1632 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1445 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 249 | 0.030 |
Why?
|
| Surface-Active Agents | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 254 | 0.030 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 205 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 329 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1496 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1248 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1410 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 43 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 502 | 0.030 |
Why?
|
| Sample Size | 1 | 2013 | 86 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1991 | 118 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 325 | 0.030 |
Why?
|
| Sheep | 1 | 2013 | 220 | 0.020 |
Why?
|
| Embolic Protection Devices | 1 | 2012 | 8 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 56 | 0.020 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 14 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2011 | 25 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2011 | 27 | 0.020 |
Why?
|
| Biopsy | 1 | 1995 | 1241 | 0.020 |
Why?
|
| Systole | 1 | 2011 | 200 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1051 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 259 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1568 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 25 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2010 | 28 | 0.020 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1991 | 144 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 121 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 344 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1991 | 301 | 0.020 |
Why?
|
| Heart Septum | 1 | 1989 | 54 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1700 | 0.020 |
Why?
|
| Caseins | 1 | 2009 | 64 | 0.020 |
Why?
|
| Heart Aneurysm | 1 | 1989 | 37 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2008 | 22 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 4585 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 70 | 0.020 |
Why?
|
| Hydrogels | 1 | 2009 | 84 | 0.020 |
Why?
|
| Fibronectins | 1 | 2008 | 110 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 687 | 0.020 |
Why?
|
| Aortic Valve | 1 | 1991 | 442 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2008 | 156 | 0.020 |
Why?
|
| Cattle | 1 | 2009 | 569 | 0.020 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1992 | 282 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 1332 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 238 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 1991 | 336 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 320 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2007 | 50 | 0.020 |
Why?
|
| Ventricular Function | 1 | 2007 | 91 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 162 | 0.020 |
Why?
|
| Desmin | 1 | 2005 | 21 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 2252 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 3312 | 0.010 |
Why?
|
| Thrombosis | 1 | 1989 | 526 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 4416 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 9093 | 0.010 |
Why?
|
| Reoperation | 1 | 2007 | 834 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 1365 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2003 | 45 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2003 | 62 | 0.010 |
Why?
|
| Philosophy, Medical | 1 | 2002 | 19 | 0.010 |
Why?
|
| Adolescent | 2 | 2018 | 19441 | 0.010 |
Why?
|
| Waiting Lists | 1 | 2004 | 228 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 817 | 0.010 |
Why?
|
| International Cooperation | 1 | 2002 | 158 | 0.010 |
Why?
|
| Age Factors | 2 | 2003 | 2831 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1111 | 0.010 |
Why?
|
| Needles | 1 | 2000 | 51 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 1520 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 3155 | 0.010 |
Why?
|
| Aluminum Silicates | 1 | 1998 | 3 | 0.010 |
Why?
|
| Yttrium | 1 | 1998 | 4 | 0.010 |
Why?
|
| Holmium | 1 | 1998 | 9 | 0.010 |
Why?
|
| Infrared Rays | 1 | 1998 | 23 | 0.010 |
Why?
|
| Coronary Vasospasm | 1 | 1998 | 11 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 1998 | 53 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2002 | 397 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1998 | 60 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 2073 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 217 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2004 | 862 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2002 | 560 | 0.010 |
Why?
|
| Calcinosis | 1 | 1998 | 179 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1995 | 53 | 0.010 |
Why?
|
| Resuscitation | 1 | 1989 | 249 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1992 | 960 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1992 | 1828 | 0.000 |
Why?
|